Picture loading failed.

Pre-Made Nemolizumab biosimilar, Whole mAb, Anti-IL31RA/IL31R Antibody: Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis. It is a monoclonal antibody that blocks the interleukin-31 receptor A. Results of a Phase II clinical trial were published in March 2017.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-372-1mg 1mg 3090
GMP-Bios-ab-372-10mg 10mg Inquiry
GMP-Bios-ab-372-100mg 100mg Inquiry
GMP-Bios-ab-372-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Nemolizumab biosimilar, Whole mAb, Anti-IL31RA/IL31R Antibody: Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 therapeutic antibody
INN Name Nemolizumab
TargetIL31R
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesChugai Pharmaceutical;Galderma;Maruho
Conditions Approvedna
Conditions ActiveAtopic dermatitis;Prurigo nodularis;Pruritus
Conditions Discontinuedna
Development Techna